CN102985819B - 肺癌生物标记及其用途 - Google Patents

肺癌生物标记及其用途 Download PDF

Info

Publication number
CN102985819B
CN102985819B CN201180033907.2A CN201180033907A CN102985819B CN 102985819 B CN102985819 B CN 102985819B CN 201180033907 A CN201180033907 A CN 201180033907A CN 102985819 B CN102985819 B CN 102985819B
Authority
CN
China
Prior art keywords
biomarker
individual
lung cancer
biomarkers
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180033907.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102985819A (zh
Inventor
S·威尔科克斯
D·艾尔斯
N·亚尼奇
L·戈尔德
M·里尔-米恩
T·贾维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Private Placement Protein Body Operation Co ltd
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Priority to CN201510123032.5A priority Critical patent/CN104777313B/zh
Publication of CN102985819A publication Critical patent/CN102985819A/zh
Application granted granted Critical
Publication of CN102985819B publication Critical patent/CN102985819B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
CN201180033907.2A 2010-07-09 2011-07-11 肺癌生物标记及其用途 Active CN102985819B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510123032.5A CN104777313B (zh) 2010-07-09 2011-07-11 肺癌生物标记及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36312210P 2010-07-09 2010-07-09
US61/363,122 2010-07-09
US201161444947P 2011-02-21 2011-02-21
US61/444,947 2011-02-21
PCT/US2011/043595 WO2012006632A2 (en) 2010-07-09 2011-07-11 Lung cancer biomarkers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510123032.5A Division CN104777313B (zh) 2010-07-09 2011-07-11 肺癌生物标记及其用途

Publications (2)

Publication Number Publication Date
CN102985819A CN102985819A (zh) 2013-03-20
CN102985819B true CN102985819B (zh) 2015-04-15

Family

ID=45441874

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180033907.2A Active CN102985819B (zh) 2010-07-09 2011-07-11 肺癌生物标记及其用途
CN201510123032.5A Active CN104777313B (zh) 2010-07-09 2011-07-11 肺癌生物标记及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510123032.5A Active CN104777313B (zh) 2010-07-09 2011-07-11 肺癌生物标记及其用途

Country Status (12)

Country Link
US (3) US20130116150A1 (enExample)
EP (1) EP2591357A4 (enExample)
JP (1) JP5905003B2 (enExample)
KR (1) KR101870123B1 (enExample)
CN (2) CN102985819B (enExample)
AU (1) AU2011274422B2 (enExample)
BR (1) BR112012032537B8 (enExample)
CA (1) CA2801110C (enExample)
IL (1) IL223295A (enExample)
MX (2) MX355020B (enExample)
SG (2) SG186953A1 (enExample)
WO (1) WO2012006632A2 (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2021792T3 (da) 2006-05-09 2013-05-21 Univ British Columbia Opløste protein-artritmarkører
AU2008329529B2 (en) 2007-11-27 2015-02-19 The University Of British Columbia 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
US8285719B1 (en) 2008-08-08 2012-10-09 The Research Foundation Of State University Of New York System and method for probabilistic relational clustering
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
DK2406633T3 (en) 2009-03-11 2019-04-01 Augurex Life Sciences Corp COMPOSITIONS AND PROCEDURES FOR CHARACTERIZING ARTHRITIC CONDITIONS
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
MX355020B (es) 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
CA2804857C (en) 2010-08-13 2021-07-06 Somalogic, Inc. Pancreatic cancer biomarkers and uses thereof
US20140235487A1 (en) * 2010-11-12 2014-08-21 William Marsh Rice University Oral cancer risk scoring
CN104011068A (zh) 2011-10-21 2014-08-27 奥古雷克斯生命科学公司 衍生自瓜氨酸化的14-3-3的抗原及其在风湿性关节炎诊断中的用途
US20130282390A1 (en) * 2012-04-20 2013-10-24 International Business Machines Corporation Combining knowledge and data driven insights for identifying risk factors in healthcare
US20150088430A1 (en) * 2012-04-26 2015-03-26 Allegro Diagnostics Corp Methods for evaluating lung cancer status
JP6022285B2 (ja) * 2012-09-28 2016-11-09 シスメックス株式会社 標本収納装置、標本収納方法、及び標本検査システム
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
JP6404822B2 (ja) 2012-10-23 2018-10-17 カリス ライフ サイエンシズ スウィッツァーランド ホールディングス ゲーエムベーハー アプタマーおよびその使用
CN104812913B (zh) 2012-11-07 2019-03-15 私募蛋白质体公司 慢性阻塞性肺疾病(copd)生物标记及其用途
EP2935628B1 (en) 2012-12-19 2018-03-21 Caris Life Sciences Switzerland Holdings GmbH Compositions and methods for aptamer screening
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
ES2773999T3 (es) 2013-03-15 2020-07-16 Somalogic Inc Biomarcadores de la enfermedad de hígado graso no alcohólico (EHGNA) y de la esteatohepatitis no alcohólica (EHNA) y usos de los mismos
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
WO2014153327A1 (en) 2013-03-18 2014-09-25 Barbeau James M Methods to determine carcinogenesis, identify markers for early cancer diagnosis and identify targets of therapy
WO2014187881A1 (en) * 2013-05-21 2014-11-27 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
KR101552014B1 (ko) 2013-10-11 2015-09-09 인제대학교 산학협력단 폐암 진단을 위한 nir의 신규한 용도
WO2015066564A1 (en) * 2013-10-31 2015-05-07 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2015068157A1 (en) 2013-11-07 2015-05-14 Medial Research Ltd. Methods and systems of evaluating a risk of lung cancer
EP3084664B8 (en) * 2013-12-16 2020-06-17 Philip Morris Products S.a.s. Systems and methods for predicting a smoking status of an individual
RU2538625C1 (ru) * 2014-01-20 2015-01-10 Денис Николаевич Бахмутов Способ диагностики рака
WO2015164617A1 (en) 2014-04-24 2015-10-29 Somalogic, Inc. Tuberculosis biomarkers in urine and uses thereof
WO2015164616A1 (en) 2014-04-24 2015-10-29 Somalogic, Inc. Biomarkers for detection of tuberculosis
WO2015164772A1 (en) * 2014-04-25 2015-10-29 Rush University Medical Center Circulating insulin-like growth factor (igf)-associated proteins for the detection of lung cancer
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
JP6775499B2 (ja) * 2014-07-14 2020-10-28 ベラサイト インコーポレイテッド 肺がん状態の評価方法
CA2961340C (en) 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
WO2016123058A1 (en) 2015-01-27 2016-08-04 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
EP3295176A1 (en) 2015-05-08 2018-03-21 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
KR102078310B1 (ko) * 2015-09-11 2020-02-19 주식회사 압타머사이언스 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법
US10546650B2 (en) 2015-10-23 2020-01-28 Google Llc Neural network for processing aptamer data
US20210215711A1 (en) 2016-02-08 2021-07-15 Somalogic, Inc. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
JP6041331B1 (ja) * 2016-02-26 2016-12-07 国立大学法人山口大学 情報処理装置と情報処理プログラム並びに情報処理方法
JP6889428B2 (ja) * 2016-02-26 2021-06-18 国立大学法人山口大学 情報処理装置と情報処理プログラム並びに情報処理方法
CN107435062B (zh) * 2016-05-25 2020-10-20 上海伯豪医学检验所有限公司 甄别肺部微小结节良恶性的外周血基因标志物及其用途
JP7058264B2 (ja) * 2016-06-08 2022-04-21 リサーチ ディヴェロプメント ファウンデーション 血管内光干渉断層撮影法を用いた冠動脈プラークの自動特徴分析およびリスク評価のためのシステムおよび方法
AU2017281099A1 (en) * 2016-06-21 2019-01-03 The Wistar Institute Of Anatomy And Biology Compositions and methods for diagnosing lung cancers using gene expression profiles
WO2018223066A1 (en) * 2017-06-02 2018-12-06 Veracyte, Inc. Methods and systems for identifying or monitoring lung disease
CN109470855B (zh) * 2017-09-08 2022-02-11 广州市丹蓝生物科技有限公司 肺癌早期诊断用蛋白芯片及试剂盒
JP2021506308A (ja) 2017-12-19 2021-02-22 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー 遺伝子発現プロファイルを使用して肺癌を診断するための組成物および方法
KR102028967B1 (ko) 2017-12-28 2019-10-07 한국원자력의학원 Ｒｉｐ1을 포함하는 폐암 전이 진단용 바이오 마커 및 이의 이용
US20210140977A1 (en) 2018-04-16 2021-05-13 University Of Cape Town A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis
BR112020026129B1 (pt) * 2018-06-22 2023-10-10 Somalogic Operating Co., Inc Métodos para melhorar o desempenho de ensaios proteômicos multiplex
WO2020018005A1 (en) * 2018-07-17 2020-01-23 Limited Liability Company "Gero" Devices, methods, compositions and systems for the treatment of aging and age- related disorders
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
AU2019371238A1 (en) * 2018-10-30 2021-06-03 Somalogic Operating Co., Inc. Methods for sample quality assessment
CN109470859A (zh) * 2018-11-04 2019-03-15 华东医院 一种外泌体蛋白作为鉴别肺结节良恶性标志物及其应用
GB2596233B (en) * 2018-12-20 2023-10-11 Veracyte Inc Methods and systems for detecting genetic fusions to identify a lung disorder
EP3671210A1 (en) * 2018-12-21 2020-06-24 Biosystems International KFT Lung cancer protein epitomic biomarkers
WO2020243574A1 (en) * 2019-05-31 2020-12-03 Delphinus Medical Technologies, Inc. Systems and methods for interactive lesion characterization
US20210027890A1 (en) * 2019-07-24 2021-01-28 ConnSante BioTech, Inc. Detecting, evaluating and predicting system for cancer risk
US20220349904A1 (en) 2019-09-03 2022-11-03 Somalogic Operating Co., Inc. Cardiovascular Risk Event Prediction and Uses Thereof
WO2021142200A1 (en) 2020-01-10 2021-07-15 Somalogic, Inc. Methods of determining impaired glucose tolerance
EP4096694A4 (en) 2020-01-30 2024-01-24 Prognomiq Inc LUNG BIOMARKERS AND METHODS OF USE THEREOF
KR20220140727A (ko) 2020-02-10 2022-10-18 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 비알코올성 지방간염 (nash) 바이오마커 및 이의 용도
KR102260915B1 (ko) 2020-02-19 2021-06-04 한국원자력의학원 폐암의 방사선 치료 예후 예측을 위한 생체 표지자
CN111876478B (zh) * 2020-04-28 2025-11-21 中国科学院微生物研究所 肺结节诊断标志物及应用
US20230304099A1 (en) * 2020-08-14 2023-09-28 The Medical College Of Wisconsin, Inc. Gene Expression Signature for Predicting Immunotherapy Response and Methods of Use
KR20230080442A (ko) * 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폐암의 검출 및 치료를 위한 방법
CN116381073A (zh) * 2020-10-10 2023-07-04 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 生物标志物在制备肺癌检测试剂中的用途和方法
KR20230085151A (ko) 2020-10-20 2023-06-13 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 심혈관 사건 위험 예측
US12334190B2 (en) 2021-03-31 2025-06-17 PrognomIQ, Inc. Multi-omic assessment using proteins and nucleic acids
GB2607436A (en) * 2021-03-31 2022-12-07 Prognomiq Inc Multi-omic assessment
EP4315366A4 (en) * 2021-03-31 2024-10-09 Prognomiq Inc MULTI-OMICS ASSESSMENT
US12387508B2 (en) 2021-09-10 2025-08-12 PrognomIQ, Inc. Direct classification of raw biomolecule measurement data
EP4402473A4 (en) 2021-09-13 2025-07-30 Prognomiq Inc ENHANCED DETECTION AND QUANTIFICATION OF BIOMOLECULES
CA3242172A1 (en) 2022-01-21 2023-07-27 David ASTLING Methods for sample quality assessment
US20250180571A1 (en) 2022-04-24 2025-06-05 Somalogic Operating Co., Inc. Methods for Sample Quality Assessment
KR20250003612A (ko) 2022-04-24 2025-01-07 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 샘플 품질 평가 방법
WO2023211771A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023211769A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023244582A1 (en) * 2022-06-13 2023-12-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Lung cancer-related biomarkers and methods of using the same
WO2024010854A1 (en) * 2022-07-07 2024-01-11 Diagnose Early, Inc. Rapid generation of breath-based health reports and systems for use in the same
EP4555327A1 (en) 2022-07-14 2025-05-21 SomaLogic Operating Co., Inc. Methods of assessing dementia risk
EP4555328A1 (en) 2022-07-14 2025-05-21 SomaLogic Operating Co., Inc. Methods for sample quality assessment
JP2025534223A (ja) 2022-09-23 2025-10-15 ソマロジック オペレーティング カンパニー インコーポレイテッド タバコ使用状態を査定する方法
US20240200125A1 (en) * 2022-12-16 2024-06-20 Droplet Biosciences, Inc. Analysis of effluent
CN116539894A (zh) * 2023-05-08 2023-08-04 复旦大学附属中山医院 Capg在制备病理性心肌肥厚检测试剂中的应用
WO2025010324A1 (en) 2023-07-06 2025-01-09 Somalogic Operating Co., Inc. Detection of target molecules in dried biologic matrices
CN120559238A (zh) * 2025-05-27 2025-08-29 中国人民解放军总医院第一医学中心 蛋白质标志物在制备用于肺磨玻璃结节良恶性鉴别的产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086443A2 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US20040254101A1 (en) 1995-06-06 2004-12-16 Human Genome Sciences, Inc. Colon specific gene and protein and cancer
WO1998039721A1 (en) 1997-03-07 1998-09-11 University Of Florida Method for diagnosing and staging prostate cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
CA2384579C (en) 1999-09-10 2010-12-07 Takashi Muramatsu Early cancer tumor marker
EP1472352A4 (en) 2000-03-06 2005-10-12 Smithkline Beecham Corp NEW COMPOUNDS
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6596503B1 (en) * 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6631330B1 (en) 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
US6576423B2 (en) 2000-12-08 2003-06-10 The Board Of Regents Of The University Of Nebraska Specific mucin expression as a marker for pancreatic cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
WO2003029273A2 (en) 2001-09-28 2003-04-10 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
US20040241653A1 (en) * 2001-12-31 2004-12-02 Elena Feinstein Methods for identifying marker genes for cancer
EP2261368A1 (en) 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
JP4679149B2 (ja) 2002-09-30 2011-04-27 オンコセラピー・サイエンス株式会社 ヒト膵癌に関連する遺伝子およびポリペプチド
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
JP4606879B2 (ja) 2002-11-15 2011-01-05 ジェノミック ヘルス， インコーポレイテッド Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
WO2004055519A2 (en) 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
EP1739185A1 (en) 2002-12-18 2007-01-03 Ciphergen Biosystems, Inc. Serum biomarkers in lung cancer
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2003900747A0 (en) 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
EP1597391B1 (en) 2003-02-20 2008-10-29 Genomic Health, Inc. Use of intronic rna to measure gene expression
US20060134120A1 (en) 2003-02-26 2006-06-22 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
WO2004099432A2 (en) 2003-05-02 2004-11-18 The Johns Hopkins University Identification of biomarkers for detecting pancreatic cancer
CN1455257A (zh) * 2003-05-23 2003-11-12 北京师范大学 一种利用表面修饰蛋白芯片进行肺癌诊断方法
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2530738C (en) 2003-06-24 2020-01-21 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP3330875B1 (en) 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
US20050069963A1 (en) 2003-08-15 2005-03-31 Lokshin Anna E. Multifactorial assay for cancer detection
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
EP1682904A2 (en) 2003-11-04 2006-07-26 Roche Diagnostics GmbH Method for distinguishing who classified aml subtypes
EP1723428A2 (en) 2004-02-19 2006-11-22 Yale University Corporation Identification of cancer protein biomarkers using proteomic techniques
EP1730308A4 (en) 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1747282B1 (en) 2004-04-15 2011-06-08 University of Florida Research Foundation, Inc. Map-2 proteolytic breakdown products as diagnostic biomarkers for neural injury
JP2007535324A (ja) 2004-04-26 2007-12-06 チルドレンズ メディカル センター コーポレーション 疾患検出のための血小板バイオマーカー
WO2006022643A1 (en) 2004-07-26 2006-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting pancreatic disease
WO2006022895A2 (en) 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
ATE483979T1 (de) 2004-08-10 2010-10-15 Oncotherapy Science Inc Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa
JP2006053113A (ja) * 2004-08-16 2006-02-23 Medical Proteoscope Co Ltd 肺腺癌リンパ節転移診断方法及び診断キット
AU2005304824B2 (en) 2004-11-05 2011-12-22 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
ES2384107T3 (es) 2004-11-05 2012-06-29 Genomic Health, Inc. Indicadores moleculares de pronóstico de cáncer de mama y predicción de la respuesta al tratamiento
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
US8632983B2 (en) 2005-04-15 2014-01-21 Van Andel Research Institute Biomarkers for pancreatic cancer and diagnostic methods
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20090005268A1 (en) 2005-07-18 2009-01-01 Epigenomics Ag Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
WO2007013665A2 (en) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2007015947A2 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
US7582441B1 (en) 2005-10-17 2009-09-01 Celera Corporation Methods and compositions for treating and diagnosing disease
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
EP1952157A4 (en) * 2005-11-10 2009-04-08 Univ Kentucky Res Found ASSAY FOR DIAGNOSIS OF LUNG CANCER
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
CA2949753A1 (en) 2005-12-22 2007-07-05 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP1974058B1 (en) 2006-01-11 2014-06-11 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
BRPI0707249A2 (pt) 2006-01-27 2011-04-26 Tripath Imaging Inc métodos para identificar pacientes com maior probabilidade de terem cáncer de ovário e composições para os mesmo
CA2641315A1 (en) 2006-02-06 2007-08-16 Tethys Bioscience, Inc. Osteoporosis associated markers and methods of use thereof
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
EP2016394A4 (en) 2006-04-04 2013-04-24 Singulex Inc METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES
EP2924440A3 (en) 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2008003024A2 (en) 2006-06-28 2008-01-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method and composition for diagnosing endometrial cancer
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
US20100184034A1 (en) 2006-11-13 2010-07-22 SOURCE PRECISION MEDICINE, INC d/b/a SOURCE MDX Gene Expression Profiling for Identification, Monitoring and Treatment of Lung Cancer
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
KR100846354B1 (ko) * 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
EP2490025A3 (en) 2007-03-27 2012-11-28 Immunovia AB Method, array and use thereof
RU2376372C2 (ru) 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
CA2681667A1 (en) * 2007-05-18 2008-11-27 Duke University Serum biomarkers for the early detection of lung cancer
US20100183514A1 (en) 2007-05-29 2010-07-22 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
CA2696431C (en) * 2007-07-17 2021-01-05 Somalogic, Inc. Method for generating aptamers with improved off-rates
EP2019318A1 (en) 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
GB0717637D0 (en) 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
US8541183B2 (en) * 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
WO2009036123A1 (en) * 2007-09-11 2009-03-19 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
US20100267041A1 (en) 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
AU2008302526A1 (en) * 2007-09-18 2009-03-26 Board Of Regents Of The University Of Texas System Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
CA2705486C (en) 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
WO2009091581A2 (en) 2008-01-18 2009-07-23 Vatrix Medical, Inc. Diagnostic biomarkers for vascular aneurysm
GB0803192D0 (en) 2008-02-22 2008-04-02 Mubio Products Bv SCLC biomarker panel
WO2009114836A1 (en) 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP2340506B1 (en) 2008-09-09 2015-11-11 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20120143805A1 (en) 2008-09-09 2012-06-07 Somalogic, Inc. Cancer Biomarkers and Uses Thereof
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20120165217A1 (en) 2008-10-06 2012-06-28 Somalogic, Inc. Cancer Biomarkers and Uses Thereof
JP5749171B2 (ja) 2008-10-30 2015-07-15 ルクセンブルグ・インスティテュート・オブ・ヘルス バイオマーカー
CA2743473C (en) 2008-11-17 2022-06-14 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
US10262103B2 (en) 2008-11-18 2019-04-16 Raphael LEHRER Individualized cancer treatment
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
JP5678045B2 (ja) 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
ES2623633T3 (es) 2009-06-09 2017-07-11 Gendiag.Exe, S.L. Marcadores de riesgo para enfermedad cardiovascular
SG10201403152QA (en) 2009-06-15 2014-08-28 Cardiodx Inc Determination of coronary artery disease risk
EP2467719A4 (en) * 2009-08-19 2013-01-09 MARKER RECOGNITION FOR CHARACTERIZING THE RISK OF CARDIOVASCULAR DISORDERS OR RESULTS COMPLICATED THEREOF
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
US9683996B2 (en) 2009-10-22 2017-06-20 The Regents Of The University Of California Assessment of solid tumor burden
EP2494364A1 (en) 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
CA2782620A1 (en) 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
US20110144914A1 (en) 2009-12-09 2011-06-16 Doug Harrington Biomarker assay for diagnosis and classification of cardiovascular disease
WO2011094483A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer
US9624547B2 (en) 2010-02-10 2017-04-18 The Regents Of The University Of California Salivary transcriptomic and proteomic biomarkers for breast cancer detection
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US20110256545A1 (en) * 2010-04-14 2011-10-20 Nancy Lan Guo mRNA expression-based prognostic gene signature for non-small cell lung cancer
MX355020B (es) 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
CA2804857C (en) 2010-08-13 2021-07-06 Somalogic, Inc. Pancreatic cancer biomarkers and uses thereof
ES2688048T3 (es) 2010-09-27 2018-10-30 Somalogic, Inc. Biomarcadores del mesotelioma y usos de los mismos
JP2014514572A (ja) * 2011-04-29 2014-06-19 キャンサー・プリヴェンション・アンド・キュア，リミテッド 分類システムおよびそのキットを使用した肺疾患の同定および診断方法
BR122019023720B1 (pt) 2011-09-30 2023-01-24 Somalogic Operating Co., Inc Kit de triagem de um indivíduo em uma população por meio de avaliação ou prognóstico do risco de um evento cardiovascular futuro dentro de um período de 5 anos
CA3006793C (en) 2011-10-24 2020-02-18 Somalogic, Inc. Non-small cell lung cancer biomarkers and uses thereof
CN104812913B (zh) 2012-11-07 2019-03-15 私募蛋白质体公司 慢性阻塞性肺疾病(copd)生物标记及其用途
EP3330277A3 (en) 2013-11-21 2018-09-26 Somalogic, Inc. Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086443A2 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer

Also Published As

Publication number Publication date
SG186953A1 (en) 2013-02-28
KR101870123B1 (ko) 2018-06-25
CN104777313A (zh) 2015-07-15
US20180275143A1 (en) 2018-09-27
BR112012032537A2 (pt) 2017-05-23
CN102985819A (zh) 2013-03-20
BR112012032537B1 (pt) 2021-03-02
IL223295A0 (en) 2013-02-03
EP2591357A2 (en) 2013-05-15
MX355020B (es) 2018-04-02
IL223295A (en) 2016-11-30
BR112012032537B8 (pt) 2022-10-18
US20120101002A1 (en) 2012-04-26
WO2012006632A3 (en) 2012-05-18
CA2801110A1 (en) 2012-01-12
US11221340B2 (en) 2022-01-11
US20130116150A1 (en) 2013-05-09
JP2013532295A (ja) 2013-08-15
CA2801110C (en) 2021-10-05
KR20130129347A (ko) 2013-11-28
EP2591357A4 (en) 2014-01-01
CN104777313B (zh) 2017-09-26
AU2011274422A1 (en) 2012-12-20
SG10201508656VA (en) 2015-11-27
WO2012006632A2 (en) 2012-01-12
MX2012014268A (es) 2013-02-12
AU2011274422B2 (en) 2016-02-11
JP5905003B2 (ja) 2016-04-20

Similar Documents

Publication Publication Date Title
CN102985819B (zh) 肺癌生物标记及其用途
CN102209968B (zh) 肺癌生物标记蛋白的捕获剂在制备试剂盒中的用途
CN106198980B (zh) 胰腺癌生物标记及其用途
CN103890586B (zh) 肺癌生物标记及其用途
US10359425B2 (en) Lung cancer biomarkers and uses thereof
US20120143805A1 (en) Cancer Biomarkers and Uses Thereof
US20220065872A1 (en) Lung Cancer Biomarkers and Uses Thereof
HK1229003B (zh) 胰腺癌生物标记及其用途
HK1229002B (en) Lung cancer biomarkers and uses thereof
HK1229002A1 (en) Lung cancer biomarkers and uses thereof
HK1229002A (en) Lung cancer biomarkers and uses thereof
HK1229003A1 (en) Pancreatic cancer biomarkers and uses thereof
HK1196429B (en) Lung cancer biomarkers and uses thereof
HK1196429A (en) Lung cancer biomarkers and uses thereof
HK1153834B (en) Lung cancer biomarkers and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Colorado, USA

Patentee after: Private placement protein body Operation Co.,Ltd.

Address before: Colorado, USA

Patentee before: SOMALOGIC, Inc.